Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloid Diseases

Interventions

DRUG: DFV890

Sponsor

Novartis Pharmaceuticals